SynAct Pharma (SYNACT) Company presentation summary

Strategic highlights and pipeline progress

• Focus on resolution therapy for inflammation, targeting both chronic autoimmune and acute viral diseases.

• Lead compound resomelagon is in advanced clinical development for rheumatoid arthritis and viral infections.

• Dual development strategy with ongoing Phase 2b ADVANCE study in RA and Phase 2 RESPIRE trial in respiratory viral infections.

• Completed financing rounds extend financial runway into 2027.

• Acquisition of TXP Pharma adds a preclinical pipeline for future growth.

Clinical development and efficacy data

• Resomelagon demonstrated significant efficacy in treatment-naive RA patients, with improved ACR response rates and reduction in disease activity.

• EXPAND study showed significant treatment effects in newly diagnosed RA patients with systemic inflammation.

• Safety profile in Phase 2 studies is favorable, with low rates of serious adverse events and manageable side effects.

• Phase 2b ADVANCE study in RA achieved recruitment goals, with topline results expected to inform Phase 3 planning.

• Clinical proof of concept in severe COVID-19 showed faster recovery and shorter hospitalization with resomelagon.

Mechanism of action and therapeutic potential

• Resomelagon is a novel biased melanocortin receptor agonist that modulates macrophages and reduces pro-inflammatory cytokines.

• Promotes endogenous resolution pathways, aiming to restore tissue function and limit chronic inflammation.

• Potential as a first-in-class, non-suppressive add-on therapy for multiple inflammatory indications.

• No stimulatory effect on melanogenesis, differentiating it from other melanocortin agonists.